Cargando…

Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline

The ATP-synthase inhibitor bedaquiline is effective against drug-resistant tuberculosis but is extremely lipophilic (clogP 7.25) with a very long plasma half-life. Additionally, inhibition of potassium current through the cardiac hERG channel by bedaquiline, is associated with prolongation of the QT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaser, Adrian, Sutherland, Hamish S., Tong, Amy S.T., Choi, Peter J., Conole, Daniel, Franzblau, Scott G., Cooper, Christopher B., Upton, Anna M., Lotlikar, Manisha, Denny, William A., Palmer, Brian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467542/ https://www.ncbi.nlm.nih.gov/pubmed/30792104 http://dx.doi.org/10.1016/j.bmc.2019.02.025

Ejemplares similares

Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles
por: Sutherland, Hamish S., et al.
Publicado: (2018)

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
por: Sutherland, Hamish S., et al.
Publicado: (2019)

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units
por: Choi, Peter J., et al.
Publicado: (2017)

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis
por: Tong, Amy S. T., et al.
Publicado: (2017)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
por: Choi, Peter J., et al.
Publicado: (2020)

Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis
por: Lu, Guo-Liang, et al.
Publicado: (2020)

Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis
por: Sutherland, Hamish S., et al.
Publicado: (2022)

TBAJ-876 Retains Bedaquiline’s Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase
por: Sarathy, Jickky Palmae, et al.
Publicado: (2019)

Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine
por: Choi, Peter J., et al.
Publicado: (2022)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Synthesis and Structure–Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-N-(Pyridin-2-ylmethyl)Pyrazolo[1,5-a]Pyrimidin-7-Amines
por: Sutherland, Hamish S., et al.
Publicado: (2022)

Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue
por: Qiao, Chang-Jiang, et al.
Publicado: (2015)

Bedaquiline micro-heteroresistance after tuberculosis treatment cessation.
por: de Vos, Margaretha, et al.
Publicado: (2019)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug’s Uncoupler Activity
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Emergence of bedaquiline resistance in a high tuberculosis burden country
por: Chesov, Elena, et al.
Publicado: (2022)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
por: Deshkar, Anuradha T, et al.
Publicado: (2022)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2021)

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China
por: Tong, Enyu, et al.
Publicado: (2023)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Almeida, Deepak, et al.
Publicado: (2021)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline
por: Berney, Michael, et al.
Publicado: (2014)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
por: Ghodousi, Arash, et al.
Publicado: (2019)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis
por: Mackenzie, Jared S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_efifmpoeikel5nrsclnl2nt6e9